Ph1 Study of ACE2016 in adults with locally advanced or met solid tumors overexpressing EGFR
Phase I Clinical Trial
A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE2016 an Allogeneic Anti-EGFR Conjugated Gamma Delta T-Cell (gdT) Therapy in Adult Subjects with Locally Advanced or Metastatic Solid Tumors Expressing the Epidermal Growth Factor Receptor (EGFR)(ACE2016-001)